Sinobioway Medicine(SZ:002581) Zheng Quan Zhi Xing·2025-07-25 16:37Group 1 - The board of directors of Shandong Weiming Bio-Pharmaceutical Co., Ltd. held its third meeting of the sixth session on July 25, 2025, with all 11 directors participating [1][2] - The board approved a financial assistance proposal to its controlling subsidiary Sichuan Gukang Pharmaceutical Co., Ltd., allowing a loan of up to 55 million RMB at an interest rate of 1.3% per annum, with a maximum term of one year [1][2] - The financial assistance does not constitute a related party transaction or a major asset restructuring, and it is deemed beneficial for Gukang Pharmaceutical's operational development [2][3] Group 2 - The board approved changes to the management structure of its wholly-owned subsidiary Xiamen Weiming Bio-Pharmaceutical Co., Ltd., appointing Chen Xing as the new legal representative and general manager, and restructuring the governance to a board of directors [1][3] - The changes at Xiamen Weiming do not require shareholder approval and will be finalized upon approval from market supervision authorities [3] - The board also approved an expansion of the business scope for its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd., which will now include various technical services and pharmaceutical production activities [4]